Abstract:Objectives: To evaluate the safety and efficacy of microwave ablation (MWA) for stage I non-small cell lung cancer (NSCLC) in patients with idiopathic pulmonary fibrosis (IPF). Materials and methods: A retrospective single-center cohort study was conducted in patients with clinical stage I NSCLC who underwent CT-guided MWA from Nov 2016 to Oct 2021. The patients were divided into the IPF group and the non-IPF group. The primary endpoints were 90-day adverse events and hospital length of stay (HLOS). The secondary endpoints included overall survival (OS) and progression-free survival (PFS). Results: A total of 107 patients (27 with IPF and 80 without IPF) were finally included for analysis. No procedure-related acute exacerbation of IPF or death occurred post-MWA. The rates of adverse events were similar between the groups (48.6% vs. 47.7%; p = 0.998). The incidence of grade 3 adverse events in the IPF group was higher than that in the non-IPF group without a significant difference (13.5% vs. 4.6%; p = 0.123). Median HLOS was 5 days in both groups without a significant difference (p = 0.078). The 1-year and 3-year OS were 85.2%/51.6% in the IPF group, and 97.5%/86.4% in the non-IPF group. The survival of patients with IPF was significantly poorer than the survival of patients without IPF (p < 0.001). There was no significant difference for PFS (p = 0.271). Conclusion: MWA was feasible in the treatment of stage I NSCLC in patients with IPF. IPF had an adverse effect on the survival of stage I NSCLC treated with MWA. Clinical relevance statement: CT-guided microwave ablation is a well-tolerated and effective potential alternative treatment for stage I non-small cell lung cancer in patients with idiopathic pulmonary fibrosis. Key points: • Microwave ablation for stage I non-small cell lung cancer was well-tolerated without procedure-related acute exacerbation of idiopathic pulmonary fibrosis and death in patients with idiopathic pulmonary fibrosis. • No differences were observed in the incidence of adverse events between patients with idiopathic pulmonary fibrosis and those without idiopathic pulmonary fibrosis after microwave ablation (48.6% vs. 47.7%; p = 0.998). • The 1-year and 3-year overall survival rates (85.2%/51.6%) in the idiopathic pulmonary fibrosis group were worse than those in the non- idiopathic pulmonary fibrosis group (97.5%/86.4%) (p < 0.001).

Percutaneous Microwave Ablation of Stage I Medically Inoperable Non‐small Cell Lung Cancer: Clinical Evaluation of 47 Cases

Microwave Ablation for Lung Cancer Patients with a Single Lung: Clinical Evaluation of 11 Cases

Safety and Effectiveness Analysis of Percutaneous Microwave Thermal Ablation Therapy Combined Brachytherapy for Lung Malignant Lesion

Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results

A Study of Microwave Ablation for Small Cell Lung Cancer.

Efficacy and Safety of Microwave Ablation in the Treatment of Patients with Oligometastatic Non-Small-cell Lung Cancer: a Retrospective Study.

Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity–Lung adenocarcinoma: A pilot study

Clinical study of microwave ablation combined with radiochemotherapy in the treatment of Stage Ⅲ peripheral non-small cell lung cancer

Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC

Safety and Clinical Outcomes of Computed Tomography‐guided Percutaneous Microwave Ablation in Patients Aged 80 Years and Older with Early‐stage Non‐small Cell Lung Cancer: A Multicenter Retrospective Study

Microwave Ablation for the Treatment of Peripheral Ground-Glass Nodule-Like Lung Cancer: Long-term Results from a Multi-Center Study.

CT‐guided Microwave Ablation in Patients with Lung Metastases from Breast Cancer

SPACES: Our Team's Experience in Lung Tumor Microwave Ablation

Advanced Non Small Cell Lung Cancer: Response to Microwave Ablation and EGFR Status

Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer in patients with comorbid idiopathic pulmonary fibrosis

Microwave Ablation Followed by Immediate Biopsy in the Treatment of Non-Small Cell Lung Cancer

Repeated Percutaneous Microwave Ablation for Local Recurrence of Inoperable Stage I Nonsmall Cell Lung Cancer

Computed tomography-guided microwave ablation for right middle lobe pulmonary nodules: a retrospective, single-center, case-control study

A Feasibility and Safety Study of Computed Tomography-Guided Percutaneous Microwave Ablation: a Novel Therapy for Multiple Synchronous Ground-Glass Opacities of the Lung

Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study